The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
Wockhardt has entered into an agreement with Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against Covid-19
Highest safety and efficacy of Sputnik V confirmed during clinical trials and in real-world use in more than 60 countries around the world
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
The company has started manufacturing the Sputnik Light vaccine
Sputnik Light as a booster significantly increases virus-neutralizing activity against Omicron based on sera 2-3 months after revaccination and is a universal booster to other vaccines inducing stronger antibody and T-cell response
Sputnik M is a new member of the Sputnik vaccines family
Subscribe To Our Newsletter & Stay Updated
